Showing 4381-4390 of 9773 results for "".
- ISDIN AGE Contour Launches for Face and Neckhttps://practicaldermatology.com/news/isdin-age-contour-launches-for-face-and-neck/2457869/ISDIN has launched ISDIN AGE Contour, a triple action face and neck cream packed with ingredients to fight three key aspects of skin aging. Formulated with a tripeptide complex con
- Estée Lauder Companies Anti-Aging Research On Skin Demonstrates Efficacy of Actives and Novel Technologies in Skin Researchhttps://practicaldermatology.com/news/este-lauder-companies-anti-aging-research-on-skin-demonstrates-efficacy-of-actives-and-novel-technologies-in-skin-research/2457874/The Estée Lauder Companies Research & Development (R&D) presented research focused on new findings in anti-aging skin research at the 2018 American Academy of Dermatology Annual Meeting in San Diego. The following reserach was presented at poster presentations at the AAD me
- Lilly: New Taltz Data and Pipeline Update to be Presented at AAD Annual Meetinghttps://practicaldermatology.com/news/lilly-new-taltz-data-and-pipeline-update-to-be-presented-at-aad-annual-meeting/2457885/Eli Lilly and Company will present new data for Taltz® (ixekizumab), baricitinib, and mirikizumab at the American Academy of Dermatology (AAD) annual meeting in San Diego. The data include eight abstracts for Tal
- Burt's Bees Sensitive Skincare Line Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/burts-bees-sensitive-skincare-line-awarded-national-eczema-association-seal-of-acceptance/2457892/The National Eczema Society (NEA) has awarded Burt's Bees' Sensitive skin care line the NEA's Seal of Acceptance, which maintains rigorous standards for approval. The Sensitive skin care line includes Burt's Bees Sensitive Facial Cleanser, Burt's Bees Sensitive Eye Cream, Burt
- FDA Approves Cosentyx Label Update to Include Scalp Psoriasishttps://practicaldermatology.com/news/fda-approves-cosentyx-label-update-to-include-scalp-psoriasis/2457896/The FDA has approved a label update for Novartis' Cosentyx (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis. The updated label includes Cosentyx data in moderate to severe scalp psoriasis—one of the difficult-to-treat for
- Research Finds Acne Linked with Increased Risk of Depressionhttps://practicaldermatology.com/news/research-finds-acne-linked-with-increased-risk-of-depression/2457898/In an analysis of one of the largest electronic medical records databases in the world, researchers found that patients with acne had a significantly increased risk of developing major depression, but only in the first 5 years after being diagnosed with acne.
- eRelevance Adds Two to Executive Leadership Teamhttps://practicaldermatology.com/news/erelevance-adds-two-to-executive-leadership-team/2457901/eRelevance has added two new names to its executive leadership team. Rafael Landestoy is now vice president of business development and Travis Skidmore is vice president of client success and retention. Mr. Landestoy will lead eRelevance&nbs
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Research Elucidates LIGHT's Role in ADhttps://practicaldermatology.com/news/research-elucidates-lights-role-in-ad/2457919/LIGHT, a member of the tumor necrosis factor (TNF) super family, directly controls the hyperproliferation of keratinocytes as well as the expression of periostin, a protein that contributes to the clinical features of atopic dermatitis and other inflammatory skin diseases such as scleroderma, rep
- FDA Accepts Ortho Dermatologics' Filing for IDP-121 Acne Treatment In Lotion Formhttps://practicaldermatology.com/news/fda-accepts-ortho-dermatologics-filing-for-idp-121-acne-treatment-in-lotion-form/2457925/The FDA has accepted Ortho Dermatologics' New Drug Application for IDP-121 (tretinoin 0.05%) lotion (Altreno) with a PDUFA action date of Aug. 27, 2018. If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.